Skip to content
Friday, November 20, 2026
Responsive Menu
Home
Healthcare Newsdesk
The Latest UK Healthcare News brought to you by NTSI
Search
Search
Home
Care Home News
Carers
Medicine & Clinical Practice
Arthritis
Brain Conditions
Cancer
Colds and Flu
Diabetes
Diet & Exercise
Eyecare
Menopause
Mens Health
Mental Wellbeing
Psychology
Rare Medical Conditions
Smoking
Women’s Health
Physiotherapy
Private Practice
Recruitment
Wellbeing at Work
Home
Clinical News
Therapy of genomic unstable solid tumours (WHO grade 3/4)in clinical stage III/IV using individualised neoantigen tumour peptides-INP trial (individualised neoantigen tumour peptides immunotherapy): study protocol for an open-label, non-randomised, prospective, single-arm trial
Clinical News
Therapy of genomic unstable solid tumours (WHO grade 3/4)in clinical stage III/IV using individualised neoantigen tumour peptides-INP trial (individualised neoantigen tumour peptides immunotherapy): study protocol for an open-label, non-randomised, prospective, single-arm trial
June 10, 2022
Lisa Baker, Editor
Post navigation
Risky sexual behaviour and HIV testing uptake among male college students: a cross-sectional study in China
Development and design validation of a novel network meta-analysis presentation tool for multiple outcomes: a qualitative descriptive study